Abstract
Advances in hepatoblastoma treatment have improved survival but have been accompanied by the chronic toxicities of pediatric cancer therapy. Cisplatin is the cornerstone of chemotherapy treatment for hepatoblastoma. The most frequent long-term complication of hepatoblastoma treatment is cisplatin-related ototoxicity. Among children who receive cisplatin, 25-90% will exhibit measurable hearing loss, impacting language and social development [1]. Therefore, efforts to identify children eligible for reduction or elimination of cisplatin-based chemotherapy while maintaining excellent oncologic outcomes are paramount in reducing the long-term toxicities of hepatoblastoma cancer treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
